Why NewLink Genetics Corp. Shares Jumped

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of NewLink Genetics Corp. (NASDAQ: NLNK  ) , a clinical-stage developer of immunotherapy treatments to fight cancer utilizing its proprietary HyperAcute immunotherapy technology platform, advanced as much as 12% after presenting positive study data on its immunotherapy candidates at the European Cancer Congress.

So what: According to NewLink's press release, the company's HyperAcute immunotherapy candidates demonstrated "greater than expected responses to salvage chemotherapy following treatment with both algenpantucel-L in patients with pancreatic cancer and tergenpumatucel-L in patients with non-small cell lung cancer (NSCLC)." Specifically, NewLink notes that three pancreatic cancer patients exhibited durable complete responses of 12 to 36 months after having progressed on algenpantucel-L therapy. Of the 16 NSCLC patients, 25% achieved stable disease while 31% demonstrated a partial response.

Now what: This is definitely good news, but I feel that investors would be wise not to get too excited just yet. We're talking about extremely early-stage immunotherapy candidates and small pool studies. If these results translate into statistically significant improvement in a much larger trial, then I feel we need to consider NewLink as a viable investment option. For the time being, it's watchlist worthy, but I'd probably suggesting waiting on investing in the company until we have more tangible mid- or late-stage results.

Two revolutionary biotechs you should be watching
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Read/Post Comments (0) | Recommend This Article (1)

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2661591, ~/Articles/ArticleHandler.aspx, 8/24/2016 5:38:48 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,481.48 -65.82 -0.35%
S&P 500 2,175.44 -11.46 -0.52%
NASD 5,217.70 -42.38 -0.81%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/24/2016 4:00 PM
NLNK $9.99 Down -0.27 -2.63%
NewLink Genetics CAPS Rating: **